Improved myocardial protection in the failing heart by selective endothelin-A receptor blockade

被引:11
|
作者
Trescher, Karola [1 ]
Bauer, Michael [1 ]
Dietl, Wolfgang [1 ]
Hallstroem, Seth [2 ]
Wick, Nikolaus [3 ]
Wolfsberger, Margarita [4 ]
Ullrich, Robert [3 ]
Juergens, Guenther [2 ]
Wolner, Ernst [1 ]
Podesser, Bruno K. [1 ]
机构
[1] Med Univ Graz, Ludwig Boltzmann Cluster Cardiovasc Res, Graz, Austria
[2] Med Univ Graz, Inst Physiol Chem, Ctr Physiol Med, Graz, Austria
[3] Vienna Med Univ, Dept Pathol, Vienna, Austria
[4] Vienna Med Univ, Dept Pediat, Vienna, Austria
来源
关键词
ANGIOTENSIN-CONVERTING ENZYME; NITRIC-OXIDE; ISCHEMIA-REPERFUSION; ANTAGONIST BOSENTAN; INJURY; INHIBITION; OVEREXPRESSION; RECOVERY;
D O I
10.1016/j.jtcvs.2008.10.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Ischemia/reperfusion injury caused by cardioplegic arrest is still a major challenge in patients with reduced left ventricular function. We investigated the effect of chronic versus acute administration of the selective endothelin-A receptor antagonist (ERA) TBC-3214Na during ischemia/reperfusion in failing hearts. Methods: Male Sprague-Dawley rats underwent coronary ligation. Three days after myocardial infarction (MI), 19 randomly assigned animals (ERA chronic) were administered TBC-3214Na continuously with their drinking water, 29 MI rats received placebo, and 3 rats died during the observation period. Six weeks after infarction, hearts were evaluated in a blood-perfused working heart model during 60 minutes of ischemia and 30 minutes of reperfusion. In 14 MI rats, TBC-3214Na ( ERA acute) was added to the cardioplegic solution during ischemia. Thirteen MI rats served as control. Results: At a similar infarct size, postischemic recovery of cardiac output (ERA chronic: 91% +/- 10%, ERA acute: 86% +/- 11% vs control: 52% +/- 15%; P < .05) and external heart work (ERA chronic: 90% +/- 10%, ERA acute: 85% +/- 13% vs control: 51% +/- 17%; P < .05) was significantly enhanced in both TBC3214Na- treated groups whereas recovery of coronary flow was only improved in ERA acute rats (ERA acute: 121% +/- 23% vs ERA chronic: 75% +/- 13%; control: 64% +/- 15%; P < .05). Blood gas measurements showed enhanced myocardial oxygen delivery and consumption with acute TBC-3214Na therapy. Additionally, high-energy phosphates (phosphocreatine) were significantly higher and transmission electron microscopy revealed less ultrastructural damage under acute TBC-3214Na administration. Conclusion: Acute endothelin-A receptor blockade is superior to chronic blockade in attenuating ischemia/reperfusion injury in failing hearts. Therefore, acute endothelin-A receptor blockade might be an interesting option for patients with heart failure undergoing cardiac surgery.
引用
收藏
页码:1005 / U243
页数:8
相关论文
共 50 条
  • [31] Cytoskeletal role in protection of the failing heart by β-adrenergic blockade
    Cheng, Guangmao
    Kasiganesan, Harinath
    Baicu, Catalin F.
    Wallenborn, J. Grace
    Kuppuswamy, Dhandapani
    Cooper, George
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2012, 302 (03): : H675 - H687
  • [32] Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease
    Kelsen, Silvia
    Hall, John E.
    Chade, Alejandro R.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2011, 301 (01) : F218 - F225
  • [33] Endothelin-A Receptor Blockade Attenuates Pulmonary Vascular Dysfunction Following Experimental Endotoxemia
    Toney, B.
    Fisher, A.
    Albrecht, M.
    Patel, N.
    Presson, R. G., Jr.
    Petrache, I.
    Lahm, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [34] Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia
    Chade, Alejandro R.
    Krier, James D.
    Textor, Stephen C.
    Lerman, Amir
    Lerman, Lilach O.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (12): : 3394 - 3403
  • [35] Endothelin-A receptor blockade prevents and reverses neonatal hypoxic pulmonary vascular remodeling
    Ambalavanan, N
    Bulger, A
    Murphy-Ullrich, J
    Engler, J
    Chen, YF
    Oparil, S
    PEDIATRIC RESEARCH, 2003, 53 (04) : 431A - 431A
  • [36] Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists
    Funk, OF
    Kettmann, V
    Drimal, J
    Langer, T
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (11) : 2750 - 2760
  • [37] Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension
    Barst, Robyn J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (01) : 95 - 109
  • [38] Endothelin receptor blockade in congestive heart failure
    Cheng, TO
    CIRCULATION, 2001, 104 (18) : E96 - E96
  • [39] Endothelin receptor blockade and exacerbation of heart failure
    Szokodi, I
    Piuhola, J
    Ruskoaho, H
    CIRCULATION, 2003, 107 (22) : E214 - E214
  • [40] Acute endothelin A receptor blockade in heart failure
    Seed, A
    McMurray, J
    CIRCULATION, 2001, 103 (18) : E94 - E94